GlassScriptPhysician profile
Anjula Chib
NPI 1952807752
$27,126.44
in general payments reported to CMS, 2019-2025
18 companies · $20K in 2025
The $20K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2022: $3,846 · 2023: $3,029 · 2024: $545 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $18K · Food and Beverage: $2,568 · Travel and Lodging: $2,287 · Education: $305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $18,000.00 |
| Food and Beverage | $2,568.20 |
| Travel and Lodging | $2,287.25 |
| Education | $304.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $18,383.76 | 2021-2025 | General - Atherectomy, General - Therapies, Avvigo Guidance System |
| Biotronik INC. | $4,420.61 | 2022-2023 | Acticor 7 Vr-T Dx, Biomonitor, Renamic Neo |
| Medtronic, INC. | $2,409.21 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $410.69 | 2022 | |
| Grifols USA, LLC | $253.87 | 2022-2024 | Prolastin-C Liquid |
| Pfizer INC. | $207.66 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.92 | 2021-2024 | Jardiance |
| Kestra Medical Technology Services, INC. | $164.86 | 2024 | Assure Wcd |
| United Therapeutics Corporation | $164.24 | 2024 | Tyvaso |
| Merck Sharp & Dohme LLC | $136.18 | 2021-2023 | Verquvo, Belsomra |
| Teleflex LLC | $130.03 | 2025 | Guideliner |
| Novo Nordisk INC | $113.48 | 2022 | |
| Abbott Laboratories | $53.18 | 2025 | Perclose Prostyle |
| Janssen Pharmaceuticals, INC | $20.65 | 2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $16.01 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $15.56 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $13.83 | 2024 | |
| Amgen INC. | $13.70 | 2024 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjula Chib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.